Health-Based Occupational Exposure Limits in Pharmaceutical or Chemical Manufacturing
Journal Title: Toxicology and Forensic Medicine – Open Journal - Year 2017, Vol 2, Issue 1
Abstract
Unexpected exposure to pharmaceuticals or chemicals at the site of manufacture can cause significant health hazards to the concerned personnel. Therefore, it is essential to protect the workplace from serious adverse effects by limiting the exposure to such chemicals to acceptable levels. Qualitative methods such as ‘a fraction of therapeutic dose’ or occupational exposure banding (OEB) are in practice and may be useful during the early periods of development, when insufficient toxicological and pharmacological data is available. However, this information is arbitrary and scientifically not defensible. With the implementation of risk-based manufacturing practices (Risk-MaP), the pharmaceutical or chemical industries are adopting a quantitative health-based approach to set an occupational exposure limit (OEL). This scientific approach utilizes all aspects of pharmacology, in vitro and in vivo toxicology, clinical therapeutics, and adverse effects profile, which will be put to perspective by qualified toxicologists to arrive at a maximum safety exposure limit. Among all, the no observed effect level (NOEL) for the most critical effect is the best starting point to derive the OEL limit. The limit at which the OEL is established related to the NOEL should be based on the presence or absence of the threshold value, the slope of the dose-response curve, the nature of the lead effect and the quality, relevance and extent of data available. The health-based OEL utilizes all the available data related to toxicology and applies scientifically acceptable daily exposure (ADE). Processes involved in OEL derivation including hazard identification, dose-response assessment, uncertainty factors analysis (e.g., interspecies, intraspecies, LOAEL to NOAEL, severity and bioavailability), measures to minimize subjectivity and the need for documentation to improve regulatory acceptance are described. Therefore, it is crucial to set or derive the OEL value for each pharmaceutical or chemical which does not pose a risk for the development of any health hazard to healthy workers in the pharmaceutical industry.
Authors and Affiliations
Vinay Kumar
Keywords
Related Articles
- EP ID EP550890
- DOI 10.17140/TFMOJ-2-115
- Views 112
- Downloads 0
Cadmium Induced Oxidative Stress in Wistar Rats: Ameliorative Effect of Quercetin and Embilica Officinalis Plant Extracts
Background: Cadmium is a naturally occurring metal that is widely distributed throughout the biosphere. The present investigation is aimed to assess the antioxidant potential of Quercitin and Embilica officinalis (amla)...
New Psychoactive Substances: Risks and Challenges
New psychoactive substances (NPS) have emerged in the last few years in response to market trends and legislative control. Only in the EU, the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) reported in...
Forensic Toxicology: The Dangers of Chasing the Single Molecule
On depictions dating from the Middle Ages, physicians are often shown holding a glass with a yellowish liquid: urine, the most accessible biological sample. Dipping their finger into the fluid and then licking it allowed...
Toxicology of Mixtures - Cd +PCBs Experimental Model
Humans are exposed to hundreds of thousands of chemicals from very different sources and the presence of more than 200 xenobiotics has been so far determined in human blood or urine.1 Hence, exposure assessment and toxi...
Effects of Exposure to Cypermethrin on the Onset of Puberty and Ovarian Biomarkers in Female Prepubertal Rat: Attenuating Role of Zinc
Cypermethrin, a synthetic pyrethyroid pesticide, is used for more than one decade to control a wide variety of pests in agriculture. The present study designed to evaluate the protective role of zinc in attenuating cyper...